Prostate cancer C61
Conditions
Interventions
Group 1: Intervention group - Approximately 12 hours before patients surgery for removal of tumor tissue, the patients performe a singel bout of exercise on a bycicle ergometer for 30 minutes at 75% o
Sponsors
Deutsche Sporthochschule Köln Institut für Kreislaufforschung ung Sportmedizin, Abteilung für molekulare und zelluläre Sportmedizin
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with diagnosed high-risc prostate cancer (PSA > 20ng/ml or biopsie gleason score 8-10 or clinical cT3 stadium); imminent resection of tumor tissue; age > 18 years
Exclusion criteria
Exclusion criteria: Neoadjuvant chemotherapy or radiation; prior chemotherapy because of prior cancer disease; thrombocytopenia < 20.000/µl; cardivascular diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Endpoint is the change of epigenetic modifications (promoter methylation) of the NKG2D gene due to the intervention. Before, after and 12 h after the single bout of exercise (IG) or rest (CG) blood samples will be drawn. Lymphocytes are attained by centrifugation with a separation medium and are used for a magnetbead isolation of NK cells (natural killer cells). DNA is extracted from NK cells and the promoter methylation of the NKG2D gene is analyzed by bisulfite treatment and real time PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Besides the primary endpoint also (1) changes of global histone acetylation in NK cells will be investigated. Therefore the cells will be stained by immunocytochemistry for histone acetylation at H4K5 and H3K9. Further (2) the NK cell cytotoxicity will be analyzed by performing cytotoxicity assays with fresh isolated NK cells and the tumor cell line K652. For this purpose the NK cells will also be characterized for their subgroups (CD56bright and CD56dim) by flow cytometry. In addition the resected tumor tissue will be under investigation for (3) the number of intratumoral NK cells and (4) the expression of NKG2D ligands on tumor cells. Both parameters will be analyzed by immunohistochemistry and evaluated microscopically. | — |
Countries
Germany
Contacts
Public ContactAlexander Schenk
Deutsche Sporthochschule Köln Institut für Kreislaufforschung und Sportmedizin Abteilung für molekulare und zelluläre Sportmedizin
Outcome results
None listed